帕尼单抗在慢性肾脏病患者中的药代动力学和安全性。
Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease.
机构信息
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2300 RC, Leiden, The Netherlands.
ZGT Pharmacy, Hospital Group Twente, Boerhaavelaan 63, 7555 BB, Hengelo, The Netherlands.
出版信息
Cancer Chemother Pharmacol. 2018 Jan;81(1):179-182. doi: 10.1007/s00280-017-3479-2. Epub 2017 Nov 23.
PURPOSE
Data on panitumumab dosing in cancer patients with renal insufficiency are lacking. Here, we report a 63-year-old metastatic colorectal cancer patient with chronic kidney injury with a glomerular filtration rate of approximately 11 mL/min.
METHODS
Pharmacokinetic parameters, including dose-normalized area under the curve, clearance and elimination half-life (T ) after the 11th and 12th infusions were estimated using trapezoidal non-compartmental methods. Data were compared to previous reported pharmacokinetic data from studies in patients with normal renal function.
RESULTS
The results show that the pharmacokinetic data in this patient with kidney failure are comparable to those in patients with adequate renal function. Moreover the treatment was well tolerated in this patient.
CONCLUSION
This study suggests that panitumumab can be safely used in cancer patients with renal impairment without dose adjustment.
目的
缺乏癌症合并肾功能不全患者使用帕尼单抗的剂量数据。在此，我们报告一例转移性结直肠癌合并慢性肾脏病患者，肾小球滤过率约为 11 mL/min。
方法
采用梯形非房室法估算第 11 次和第 12 次输注后剂量归一化曲线下面积、清除率和消除半衰期（T ）的药代动力学参数。将数据与肾功能正常患者的研究中之前报道的药代动力学数据进行比较。
结果
结果表明，该肾功能衰竭患者的药代动力学数据与肾功能正常患者的数据相当。此外，该患者对治疗的耐受性良好。
结论
本研究表明，无需调整剂量，帕尼单抗可安全用于合并肾功能损害的癌症患者。
Zotero 插件